On the Impossible: Why Cassava Sciences’ simufilam will fail Phase 3 clinical trials and the stock will trade to $2
The text analyzes Cassava Sciences' simufilam, predicting its failure in Phase 3 trials for Alzheimer's disease due to ineffective mechanisms, poor pharmacokinetics, and manipulative data practices.
Sports betting legalization reduces net investments of households by nearly 14% overall.
$1 of sports betting reduces net investment
by over $2, increases credit card debt, but has no effect on participation in lotteries or other online gambling
outlets.
https://t.co/k8JRSvj6Da https://t.co/qfDt80KbGw